The cost of Kisqali (ribociclib) in combination with Faslodex (fulvestrant) for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer can vary. For example, a 2023 report indicated that a month's supply of Kisqali, which is a 200 mg tablet taken three times daily, could cost approximately $12,000 before insurance or assistance programs [1]. This price reflects the drug's formulation and targeted therapy approach.
How can I lower the cost of Kisqali?
Patients may be able to reduce their out-of-pocket expenses for Kisqali through various financial assistance programs. Novartis, the manufacturer of Kisqali, offers programs like the Kisqali Co-Pay Program, which can provide eligible commercially insured patients with as little as a $0 co-pay for their monthly prescription [2]. Additionally, patients may qualify for patient assistance programs if they meet certain income or insurance criteria [3].
What is the typical dosage and treatment duration for Kisqali?
Kisqali is typically prescribed as a 200 mg tablet taken orally three times a day, on a 21-day cycle, followed by 7 days off. It is often given in combination with other medications, such as Faslodex or an aromatase inhibitor [1]. The duration of treatment depends on the individual patient's response to the therapy and their physician's recommendation.
When does the patent for Kisqali expire?
Patent expiration dates are crucial for understanding when generic versions of a drug might become available, potentially lowering costs. Information regarding the specific patent expiries for Kisqali can be found through resources like DrugPatentWatch.com [4]. These patents can sometimes be extended or challenged, influencing the timeline for generic competition.
How does Kisqali compare to other breast cancer treatments?
Kisqali is a cyclin-dependent kinase (CDK) 4/6 inhibitor. This class of drugs works by blocking specific proteins that help cancer cells grow and divide [5]. It is commonly used in combination with endocrine therapy for certain types of advanced breast cancer. Other CDK 4/6 inhibitors available include abemaciclib (Verzenio) and palbociclib (Ibrance), which also have their own cost structures and patent landscapes [4].
What are the potential side effects of Kisqali?
Common side effects associated with Kisqali treatment can include neutropenia (low white blood cell count), nausea, vomiting, diarrhea, fatigue, hair loss, and liver enzyme elevations [1]. Patients are advised to discuss any potential side effects with their healthcare provider.
What is the role of Faslodex in combination with Kisqali?
Faslodex (fulvestrant) is a type of endocrine therapy that works by blocking the estrogen receptor, which is often present in hormone receptor-positive breast cancer cells. When used in combination with Kisqali, Faslodex targets different pathways involved in cancer growth, offering a more comprehensive treatment approach for eligible patients [1].
What are the clinical trial results for Kisqali?
Clinical trials have demonstrated that the combination of Kisqali with endocrine therapy can significantly improve progression-free survival and overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer [1]. Specific trial data, such as the MONALEESA trials, provide detailed outcomes on efficacy and safety.
Who manufactures Kisqali?
Kisqali is manufactured by Novartis [1].
Sources:
[1] https://www.kisqali.com/
[2] https://www.kisqali.com/financial-assistance
[3] https://www.novartisoncology.com/patient-support/patient-assistance-programs
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-novel-drugs